Your Gut May Know You’re Getting Parkinson’s Before You Do

Nearly ten years ago, I wrote about the gut’s connection to Parkinson’s disease (PD) in The Mind-Gut Connection. In my clinic, I’d been using sudden-onset constipation in midlife as one of the earliest warning signs — something that can precede a PD diagnosis by a decade. What we’ve lacked, despite a growing pile of studies showing microbiome differences in PD patients, is hard evidence that specific microbes actually cause the disease, not just accompany it. That may be starting to change.

A new study published in Nature Medicine finds that the bacteria living in your intestines may carry detectable signs of Parkinson’s risk years before any tremor or stiffness appears. If the findings hold up, they could shift how doctors approach early screening for this disease.

The growing crisis of Parkinson’s disease

Parkinson’s disease is already the fastest-growing neurological disorder in the world, and the numbers keep climbing. The economic cost in the U.S. alone is projected to rise from $52 billion in 2017 to $79 billion by 2037. The disease destroys dopamine-producing brain cells, and by the time someone gets a diagnosis, more than half of those cells are already gone. There’s no cure. Treatments manage symptoms but don’t touch the underlying damage.

Early detection is both the most important goal and the hardest one. Scientists have long suspected that some forms of PD don’t begin in the brain at all, but somewhere more unexpected: the gut.

The gut-brain connection

Your digestive tract is home to roughly 38 trillion microbial organisms — bacteria, fungi, archaea, and other microscopic life — collectively called the gut microbiome. This ecosystem talks constantly with the brain through what I call the brain-gut microbiome system: a two-way network of nerve signals, hormones, and immune molecules. Disruptions to that microbial balance, known as dysbiosis, have been linked to conditions ranging from depression to autoimmune disorders — and, increasingly, to PD.

For years, researchers have noticed that PD patients frequently experience REM sleep disturbances, constipation, and other gut problems long before motor symptoms appear. Some scientists believe this is because the disease starts not in the brain but in the enteric nervous system — the nerve network embedded in the gut wall — and travels upward through the vagus nerve. Under this “body-first” hypothesis, the gut microbiome could be both an early driver of the disease process and a window into who is quietly heading toward it.

A three-way comparison

The new study, conducted by a large international team based primarily at University College London and France’s INRAE research institute, recruited 464 participants across three groups: 271 people already diagnosed with PD, 150 healthy controls, and — importantly — 43 completely asymptomatic people carrying a mutation in a gene called GBA1 but showing no Parkinson’s symptoms.

The GBA1 gene is worth understanding. Variants in it are the most common known genetic risk factor for PD, raising lifetime risk up to 30-fold. Yet only about 10–20% of carriers actually develop the disease. Why? That’s been one of the central unanswered questions in PD research, and this study offers a possible piece of the answer.

The researchers used shotgun metagenomics — a technique that sequences all the bacterial DNA in a stool sample — to identify microbial species across all three groups. They then applied a statistical measure called Cliff’s delta to assess not just which species differed between groups, but how consistently those differences appeared across all three.

The intermediate microbiome

About 25% of all microbial species in the gut showed meaningful differences between PD patients and healthy controls. That alone wasn’t new; previous studies had found similar patterns. What was new was what happened when they looked at the gene carriers who had no symptoms yet.
The microbiomes of these at-risk individuals were already moving in the wrong direction. Not yet as disrupted as those of people with full-blown PD, but measurably different from healthy controls. Their gut bacteria had already begun to shift toward a disease pattern, even while their brains and bodies appeared completely normal.

Species elevated in Parkinson’s patients — including Streptococcus mutans, Bifidobacterium dentium, and Lactobacillus paragasseri — were already ticking upward in the gene carriers. Species depleted in Parkinson’s — particularly butyrate-producing bacteria like Roseburia intestinalis and various Faecalibacterium species — were already declining. Butyrate matters here: it’s a short-chain fatty acid produced when gut microbes ferment dietary fiber, and it has well-documented anti-inflammatory effects. Its depletion is one of the more consistent findings across gut-brain disease research.

More altered microbiomes, worse symptoms

The relationship between microbiome disruption and clinical severity was dose-dependent. Among PD patients, those with the most altered microbiomes also had more severe depression, worse autonomic dysfunction (problems with heart rate, bladder control, and digestion), more severe constipation, and longer disease duration. Poorer diet quality and prior appendix removal were also more common in this group — both factors previously linked to PD risk, though the appendix connection is still debated.

Among the symptom-free genetic carriers, every single individual who met formal criteria for “prodromal Parkinson’s disease” — meaning they showed early warning signs like sleep disturbances or subtle motor changes — had microbiome alterations above the group’s median. Four of them sat at the very top of the distribution, with the most Parkinson’s-like gut profiles of anyone in the at-risk group.

Even healthy people show warning signs

The finding I keep returning to involves the healthy controls with no known genetic risk at all. When researchers sorted these individuals by how PD-like their microbiomes looked, about 20% showed notable disruptions. These individuals had more depression, worse autonomic function, poorer diets, and higher rates of constipation than peers with healthier gut profiles. The researchers propose that some of them may already be progressing toward Parkinson’s — undetected, undiagnosed, and currently invisible to medicine.

To act on this, the team developed a preliminary scoring tool called PDMS-16, based on the presence or absence of 16 specific bacterial species. In healthy controls, high PDMS-16 scores predicted a more PD-like clinical profile, even among people with no neurological diagnosis and no genetic predisposition.

The findings were validated in three independent cohorts from the United States, Korea, and Turkey — over 950 participants total — which gives them reasonable cross-cultural weight.

What this means

A simple stool test for Parkinson’s isn’t around the corner, and I’d be skeptical of any company that implies otherwise using this study’s data. The study is cross-sectional — it captured one moment in time rather than following people forward to see who actually developed the disease. Larger, longer studies are needed, and they’ll need to account for environmental factors like diet, chemical exposures, and microplastics that may influence who actually progresses.

But the direction this research points is worth paying attention to. A future in which routine genetic and microbiome screening flags people at neurological risk years before brain damage begins — while there’s still time to intervene — is no longer just theoretical. We’re building the evidence base for it right now.